Patient Dies in BMS Multiple Sclerosis CAR T Trial; Company Cannot Link Death to Drug
· techtimes.com · popularity 21/100 · 0 similar stories today · Cancer & Oncology (Health & Life Sciences)
Read the original at techtimes.com →
Summary
CAR T therapy multiple sclerosis trial death: Bristol Myers Squibb disclosed the first fatality in its Phase 1 Breakfree-2 study, with a patient dying 44 days post-infusion from septic pneumonia. BMS says it cannot yet attribute the death to zola-cel, citing confounding factors, and is targeting a 2027 restart pending FDA interaction.
Found in: Tech Times. Rating basis: single outlet; outlet tier 2 (unlisted); 1 feeds; feed position 1.